Table 1.
Clinical characteristics
| Variable | |
|---|---|
| Subjects (N) | 50 |
| Age (years) | 58±13 |
| Male (N [%]) | 43 [86] |
| BMI (kg/cm2) | 27.0±5.1 |
| Smoking (N [%]) | 16 [32] |
| Hypertension (N [%]) | 31 [62] |
| Diabetes mellitus (N [%)) | 16 [32] |
| Dyslipidemia (N [%]) | 15 [30] |
| ARB (N [%]) | 8 [16] |
| ACE-I (N [%]) | 2 [4] |
| Ca channel blocker (N [%]) | 6 [12] |
| SBP (mm Hg) | 129.6±18.9 |
| DBP (mm Hg) | 80.3±10.4 |
| HR (bpm) | 72.2±10.4 |
| Polysomnography | |
| AHI (/hour) | 44.6±22.5 |
| OAI (/hour) | 16.0±19.4 |
| CAI (/hour) | 1.1±2.9 |
| HI (/hour) | 25.4±15.2 |
| TST (minute) | 392±81 |
| 3%ODI (/hour) | 33.5±19.9 |
| Averaged SpO2 (%) | 94.0±1.8 |
| Lowest SpO2 (%) | 74.9±9.6 |
| SpO2 < 90% (%) | 8.1±9.0 |
| TDS (% × hour) | 38.8±11.5 |
| FMD data | |
| Arterial diameter (mm) | 4.3±0.6 |
| %FMD (%) | 4.2±2.3 |
Abbreviations: N, number; BMI, body mass index; ARB, angiotensin receptor blocker; ACE-I, angiotensin-converting enzyme inhibitor; Ca, calcium; FMD, flow-mediated vasodilation; SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; PSG, polysomnography; AHI, apnea-hypopnea index, OAI, obstructive apnea index; CAI, central apnea index; HI, hypopnea index; TST, total sleep time; SpO2, arterial oxygen saturation; ODI, oxygen desaturation index; TDS, time desaturation summation index.